drugset / Trial / NCT05208177
A Study of SHR-1802 in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT)，recommended phase II dose (RP2D) and assess objective response rate (ORR) assessed by the investigator based on RECIST v1.1 criteria.
Timeline
- Start
- 2022-04-22
- Primary completion
- 2023-08-18
- Completion
- 2023-08-18
Outcome
Outcome not reported
Stopped (Business): “Adjustment of R\&D strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Famitinib | Small molecule | — | — |
| Subject | SHR-1802 | Monoclonal antibody | — | — |